Sionna Therapeutics, Inc. Sample Contracts
Sionna Therapeutics, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • February 3rd, 2025 • Sionna Therapeutics, Inc. • Pharmaceutical preparations
SIONNA THERAPEUTICS, INC. INDEMNIFICATION AGREEMENT (For Directors of a Delaware Corporation)Indemnification Agreement • February 3rd, 2025 • Sionna Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of [•] by and between Sionna Therapeutics, Inc., a Delaware corporation (the “Company”), and [•] (“Indemnitee”).
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • January 17th, 2025 • Sionna Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of March 4, 2024, by and among Sionna Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
SUMMARY OF BASIC LEASE INFORMATIONLease • January 17th, 2025 • Sionna Therapeutics, Inc. • Pharmaceutical preparations
This Lease, which includes the preceding Summary and the exhibits attached hereto and incorporated herein by this reference (the Lease, the Summary and the exhibits to be known sometimes collectively hereafter as the “Lease”), dated as of the date set forth in Section 1 of the Summary, is made by and between BP3-BOS6 21 HICKORY LLC, a Delaware limited liability company (“Landlord”), and SIONNA THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...License Agreement • January 17th, 2025 • Sionna Therapeutics, Inc. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) is made and entered into as of December 20, 2019 (the “Effective Date”) by and between Sanofi, a French corporation (acting on its own behalf and on behalf of its Affiliates, “Sanofi”) and Sling Therapeutics, Inc., a Delaware corporation (“Licensee”). Sanofi and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...License Agreement • January 17th, 2025 • Sionna Therapeutics, Inc. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) is made and entered into effective July 11, 2024 (the “Effective Date”) by and between AbbVie Global Enterprises Ltd., a corporation organized under the laws of Bermuda and having a principal place of business at Thistle House, 4 Burnaby Street, Hamilton Pembroke HM 11, Bermuda (“AbbVie”), and Sionna Therapeutics, Inc., a Delaware corporation and having a principal place of business at 21 Hickory Drive, Suite 500, Waltham, MA 02451 (“Sionna”). AbbVie and Sionna are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Payment Agreement • January 17th, 2025 • Sionna Therapeutics, Inc. • Pharmaceutical preparations • New York
This Payment Agreement (this “Agreement”) is made and entered into as of December 20, 2019 (the “Effective Date”) by and between Cystic Fibrosis Foundation, a Delaware not-for-profit corporation (“CFF”) and Sling Therapeutics, Inc., a Delaware corporation (“Sling”). CFF and Sling are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
SIONNA THERAPEUTICS, INC. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENTSales Agreement • March 2nd, 2026 • Sionna Therapeutics, Inc. • Pharmaceutical preparations • New York
Sionna Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:
SLING THERAPEUTICS, INC.Employment Agreement • January 17th, 2025 • Sionna Therapeutics, Inc. • Pharmaceutical preparations
On behalf of Sling Therapeutics, Inc., a Delaware corporation (the “Company”), I am pleased to offer you the position of the Company’s President and Chief Executive Officer and (“CEO”). If accepted, this letter agreement sets forth the terms and conditions of your employment (the “Agreement”).
SLING THERAPEUTICS, INC. Natick, MA 01760Employment Agreement • January 17th, 2025 • Sionna Therapeutics, Inc. • Pharmaceutical preparations
On behalf of Sling Therapeutics, Inc., a Delaware corporation (the “Company”), I am pleased to offer you the position of the Company’s Chief Financial Officer and (“CFO”). If accepted, this letter agreement sets forth the terms and conditions of your employment (the “Agreement”).
SLING THERAPEUTICS, INC.Employment Agreement • January 17th, 2025 • Sionna Therapeutics, Inc. • Pharmaceutical preparations
On behalf of Sling Therapeutics, Inc., a Delaware corporation (the “Company”), I am pleased to present this letter as the Company’s formal offer to you to serve in the position of the Company’s Chief Medical Officer (“CMO”). If accepted, this letter agreement sets forth the terms and conditions of your employment (the “Agreement”).